The NADINA Trial - A Paradigm Shift in Melanoma Treatment

Oncology Data Advisor

M. Hadfield

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

ASCO® 2024 Summary: "My Personal Highlights in Melanoma"

2024 ASCO® Annual Meeting Insights Hub

S. Patel

Dysplastic Nevi: Navigating the Risk Landscape

Scripps Health

B. Kelley

Sun Safety and Melanoma Awareness: Expert Tips on Preventing Sun Dam…

Oncology Data Advisor

T. Knight, M. Hadfield

ESMO 2024 Summary: Metastatic Melanoma Highlights

2024 ESMO Annual Meeting Insights Hub

C. Blank

The Role of Adjuvant IO vs. Targeted Therapy for BRAF V600-Mutant St…

Tarek Haykal

ESMO 2024 Summary: Developmental Therapeutics Highlights

2024 ESMO Annual Meeting Insights Hub

G. Sonpavde

Optimal Treatment for BRAF-Mutated Metastatic Melanoma

Jeff Yorio

Advances in the Treatment of Melanoma

Masterclasses in Dermatology

D. Fisher

New Frontiers in Oncology: Advanced Diagnostics and Therapeutics

Springer Healthcare IME

S. Peters

ESMO 2024 Summary: Key Metastatic and Neoadjuvant Melanoma Trials

2024 ESMO Annual Meeting Insights Hub

D. Johnson

ASCO® 2024 Summary: "Highlights in Early Stage, 1L Metastatic, and R…

2024 ASCO® Annual Meeting Insights Hub

D. Johnson

ASCO® 2024 Insights: "RELATIVITY-047 Trial 3-Year OS and MSS Outcome…

2024 ASCO® Annual Meeting Insights Hub

H. Tawbi

AAD 2024 Insights: What's New In Nail Tumors

AAD 2024

J. Dominguez-Cherit

FDA Approval of Lifileucel for Unresectable or Metastatic Melanoma: …

Stanford Medicine

A. Betof Warner

Biomarkers for Immunotherapy in Melanoma: Where Are We Now?

Vanderbilt University Medical Center (VUMC)

D. Johnson

Year in Review 2024 - Melanoma

Oncology 2024 Year in Review

A. van Akkooi

Checkpoint Inhibitors, Arthritis and Other Autoimmune Triggers

West Virginia State Rheumatology Society

J. Bustamante

Systemic Therapies for Melanoma and Immune Related Adverse Effects (…

Melanoma Research Foundation

S. Chandra